United Therapeutics Total Current Assets decreased by 22.4% to $2.87B in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 27.1%, from $3.94B to $2.87B. Over 5 years (FY 2020 to FY 2025), Total Current Assets shows an upward trend with a 11.3% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Higher levels indicate stronger short-term liquidity, though excessive levels may suggest inefficient capital allocation.
The sum of all assets that are expected to be converted into cash or consumed within one year. This provides a snapshot...
Compared against current liabilities to determine the current ratio, a standard measure of short-term financial health.
total_current_assets| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $2.32B | $2.39B | $2.32B | $2.59B | $2.68B | $3.06B | $3.38B | $3.19B | $3.21B | $3.46B | $3.55B | $3.25B | $3.62B | $4.00B | $3.87B | $3.94B | $3.83B | $3.49B | $3.70B | $2.87B |
| QoQ Change | — | +2.9% | -2.6% | +11.3% | +3.8% | +13.9% | +10.6% | -5.5% | +0.6% | +7.6% | +2.7% | -8.5% | +11.4% | +10.5% | -3.2% | +1.7% | -2.9% | -8.7% | +6.0% | -22.4% |
| YoY Change | — | — | — | — | +15.8% | +28.1% | +45.5% | +23.4% | +19.7% | +13.2% | +5.0% | +1.7% | +12.6% | +15.7% | +9.1% | +21.3% | +5.7% | -12.7% | -4.4% | -27.1% |